
ARCA biopharma ABIO
Quarterly report 2025-Q3
added 11-12-2025
ARCA biopharma P/E Ratio 2011-2026 | ABIO
Annual P/E Ratio ARCA biopharma
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -5.78 | -4.27 | -3.02 | -1.36 | -2.61 | -1.27 | -0.768 | -1.02 | -1.4 | -2.08 | -1.5 | -2.49 | -2.1 | -1.85 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -0.768 | -5.78 | -2.25 |
P/E Ratio of other stocks in the Biotechnology industry
| Issuer | P/E Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
-0.612 | - | 2.43 % | $ 254 M | ||
|
Acorda Therapeutics
ACOR
|
-0.0662 | - | -24.86 % | $ 820 K | ||
|
AbbVie
ABBV
|
220 | $ 208.84 | -2.86 % | $ 369 B | ||
|
AbCellera Biologics
ABCL
|
-6.57 | $ 3.52 | 0.28 % | $ 1.05 B | ||
|
Grifols, S.A.
GRFS
|
31.7 | $ 8.24 | -0.12 % | $ 6.83 B | ||
|
Ascendis Pharma A/S
ASND
|
-19.2 | $ 229.25 | 0.44 % | $ 5 B | ||
|
I-Mab
IMAB
|
-0.236 | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
55.7 | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
2.49 K | - | 2.54 % | $ 160 B | ||
|
Biophytis SA
BPTS
|
-17.6 | - | -13.47 % | $ 169 M | ||
|
Aeterna Zentaris
AEZS
|
-4.94 | - | 5.93 % | $ 314 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-3.48 | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-1.71 | - | - | $ 26.5 M | ||
|
Akero Therapeutics
AKRO
|
-12.9 | - | - | $ 3.67 B | ||
|
Midatech Pharma plc
MTP
|
-14.5 | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-3.57 | - | -1.52 % | $ 24.7 M | ||
|
ANI Pharmaceuticals
ANIP
|
-64.6 | $ 74.21 | -2.3 % | $ 1.43 B | ||
|
Adverum Biotechnologies
ADVM
|
-0.583 | - | - | $ 86.2 M | ||
|
Advaxis
ADXS
|
-0.0388 | - | -9.65 % | $ 45.9 M | ||
|
Autolus Therapeutics plc
AUTL
|
-1.12 | $ 1.41 | 2.17 % | $ 375 M | ||
|
AgeX Therapeutics
AGE
|
-0.00095 | - | -10.17 % | $ 12.2 K | ||
|
Cocrystal Pharma
COCP
|
-1.29 | $ 1.51 | 48.04 % | $ 17 M | ||
|
Applied Molecular Transport
AMTI
|
-0.175 | - | - | $ 10.1 M | ||
|
AIkido Pharma
AIKI
|
-1.33 | - | 1.93 % | $ 17.4 M | ||
|
Akouos
AKUS
|
-1.98 | - | 0.23 % | $ 488 M | ||
|
Институт стволовых клеток человека
ISKJ
|
38.8 | - | - | - | ||
|
Allena Pharmaceuticals
ALNA
|
-2.17 | - | 3.16 % | $ 1.9 M | ||
|
BioMarin Pharmaceutical
BMRN
|
33.5 | $ 55.5 | -3.04 % | $ 10.6 B | ||
|
Alpine Immune Sciences
ALPN
|
-4.65 | - | - | $ 2.17 B | ||
|
Aileron Therapeutics
ALRN
|
-0.608 | - | 10.36 % | $ 9.8 M | ||
|
Arcturus Therapeutics Holdings
ARCT
|
-3.3 | $ 8.03 | 2.29 % | $ 220 M | ||
|
Adaptive Biotechnologies Corporation
ADPT
|
-41.7 | $ 14.81 | 2.63 % | $ 2.25 B | ||
|
Altimmune
ALT
|
-3.61 | $ 3.34 | 7.05 % | $ 294 M | ||
|
BioNTech SE
BNTX
|
6.11 | $ 91.18 | 1.97 % | $ 27.2 B | ||
|
Amgen
AMGN
|
25.7 | $ 347.94 | -1.51 % | $ 187 B | ||
|
Aurinia Pharmaceuticals
AUPH
|
8.83 | $ 15.61 | 0.9 % | $ 2.1 B | ||
|
Bristol-Myers Squibb Company
BMY
|
17.3 | $ 59.6 | -2.45 % | $ 121 B | ||
|
Aptose Biosciences
APTO
|
-0.0913 | - | -45.71 % | $ 1.2 M | ||
|
Aptinyx
APTX
|
-0.146 | - | -39.0 % | $ 4.57 M | ||
|
CureVac N.V.
CVAC
|
-8.58 | - | - | $ 867 M | ||
|
Burford Capital Limited
BUR
|
12.2 | $ 4.14 | -2.59 % | $ 683 M | ||
|
BioCryst Pharmaceuticals
BCRX
|
-19.3 | $ 9.02 | -3.84 % | $ 1.86 B | ||
|
Avenue Therapeutics
ATXI
|
-0.0467 | - | -52.27 % | $ 4.45 M | ||
|
Atea Pharmaceuticals
AVIR
|
-2.69 | $ 5.76 | 1.95 % | $ 469 M | ||
|
BeiGene, Ltd.
BGNE
|
-392 | - | 0.49 % | $ 251 B | ||
|
AVROBIO
AVRO
|
4.63 | - | 1083.1 % | $ 745 M | ||
|
Cellectis S.A.
CLLS
|
-1.62 | $ 3.41 | 1.19 % | $ 116 M | ||
|
Biogen
BIIB
|
22.7 | $ 177.34 | -3.5 % | $ 26 B | ||
|
Axcella Health
AXLA
|
-0.308 | - | -16.42 % | $ 249 M | ||
|
Axon Enterprise
AXON
|
106 | $ 412.81 | -2.54 % | $ 31.3 B |